直接抗病毒治疗对单纯HCV感染及HIV-HCV合并感染伴混合型冷球蛋白血症患者的获益
本研究分析了35例HCV单纯感染和12例HIV-HCV合并感染伴混合型冷球蛋白血症患者接受DAA治疗后的冷球蛋白清除及症状影响。总体SVR12率为100%,随访结束时34%(16/47)患者冷球蛋白血症持续存在;持续者冷球蛋白中位水平从治疗开始时的101.4 mg/L降至随访结束时的51.7 mg/L。结论认为DAA诱导的SVR可使三分之二患者的冷球蛋白清除。
要点
- DAA治疗总体SVR12率为100%。
- 随访结束时34%(16/47)患者冷球蛋白血症持续存在。
- 持续者冷球蛋白中位水平从101.4 mg/L降至51.7 mg/L。
核心结论
- DAA诱导的持续病毒学应答可使三分之二患者的冷球蛋白清除。
研究设计与样本
- 分析35例HCV单纯感染和12例HIV-HCV合并感染伴症状性或无症状性混合型冷球蛋白血症、接受DAA方案治疗的患者。
- 在DAA开始治疗时、治疗期间不同时间点及治疗后评估冷球蛋白水平,直至冷球蛋白清除(如有)。
主要发现
- 中位年龄61岁,51%(24/47)为男性。
- HIV患者经联合抗逆转录病毒治疗HIV RNA均检测不到。
- 混合型冷球蛋白血症有症状者在HCV单纯感染组为77%(27/35),在HIV-HCV合并感染组为8%(1/12)(p < 0.001)。
- 51%(24/47)患者为既往聚乙二醇干扰素/利巴韦林(PEG-IFN/RBV)治疗无应答者,32%(15/47)为肝硬化患者。
- 1例患者接受DAA + PEG-IFN/RBV,其余均接受无干扰素DAA方案;总体SVR12率为100%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Mixed cryoglobulinaemia (MC) is found in 40-60% of patients with chronic hepatitis C virus (HCV) infection. Direct-acting antiviral (DAA) regimens considerably improve clinical outcome of HCV infection with sustained virological response rates (SVR) above 90%. We aimed to evaluate the impact of DAA therapy on cryoglobulin clearance and on MC-related symptoms in patients with HCV-associated MC. METHODS: Thirty-five HCV-monoinfected and 12 HIV-HCV-coinfected patients with symptomatic or asymptomatic MC treated with DAA regimen were analysed. Cryoglobulin levels were assessed at DAA initiation, at different time points during treatment and after treatment and until cryoglobulin clearance if any. RESULTS: Median age was 61 years and 51% (24/47) were males. HIV patients had all undetectable HIV RNA with combined antiretroviral therapy. MC was symptomatic in 77% (27/35) of HCV-monoinfected patients and in 8% (1/12) of HIV-HCV-coinfected patients (p < 0.001). Fifty-one per cent (24/47) of patients were previous non-responders to pegylated-interferon/ribavirin (PEG-IFN/RBV) therapy and 32% (15/47) were cirrhotics. One patient received DAA + PEG-IFN/RBV and all others received an IFN-free DAA regimen. The overall SVR12 rate was 100%. Cryoglobulinaemia persisted in 34% (n = 16/47) of patients at the end of follow-up: 17% (2/12) of HIV-HCV-coinfected and 40% (14/35) of HCV-monoinfected patients. Among these patients, median cryoglobulin level decreased from 101.4 mg/L at DAA treatment initiation to 51.7 mg/L at the end of follow-up. CONCLUSIONS: DAA-induced SVR allows cryoglobulin clearance in two-thirds of patients.
引用
- Miailhes P, Hartig-Lavie K, Virlogeux V, et al. Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia. Clin Microbiol Infect. 2018. PMID: 29870852. doi:10.1016/j.cmi.2018.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。